Stryker Co. (SYK) Shares Sold by Edmp Inc.

Edmp Inc. decreased its stake in shares of Stryker Co. (NYSE:SYK) by 1.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,590 shares of the medical technology company’s stock after selling 140 shares during the quarter. Stryker makes up 2.8% of Edmp Inc.’s portfolio, making the stock its 14th largest position. Edmp Inc.’s holdings in Stryker were worth $2,882,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. RPG Investment Advisory LLC raised its holdings in shares of Stryker by 160.0% in the 1st quarter. RPG Investment Advisory LLC now owns 156 shares of the medical technology company’s stock valued at $31,000 after purchasing an additional 96 shares in the last quarter. ERTS Wealth Advisors LLC bought a new stake in shares of Stryker in the 4th quarter valued at about $25,000. Northwest Wealth Management LLC raised its holdings in shares of Stryker by 103.6% in the 4th quarter. Northwest Wealth Management LLC now owns 169 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 86 shares in the last quarter. Semmax Financial Advisors Inc. bought a new stake in shares of Stryker in the 4th quarter valued at about $28,000. Finally, Horan Securities Inc. bought a new stake in shares of Stryker in the 4th quarter valued at about $30,000. Institutional investors own 74.61% of the company’s stock.

Several research firms have recently commented on SYK. Canaccord Genuity boosted their price target on shares of Stryker from $185.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday, January 30th. Zacks Investment Research upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $199.00 price target for the company in a report on Monday, February 4th. Morgan Stanley reduced their price target on shares of Stryker from $212.00 to $197.00 and set an “overweight” rating for the company in a report on Wednesday, January 2nd. Royal Bank of Canada boosted their price target on shares of Stryker from $184.00 to $204.00 and gave the company an “outperform” rating in a report on Monday, March 11th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Stryker in a report on Friday, January 18th. Eight equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $192.13.

In other Stryker news, Chairman Kevin Lobo sold 41,750 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $194.11, for a total transaction of $8,104,092.50. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Timothy J. Scannell sold 4,666 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $186.25, for a total transaction of $869,042.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 125,789 shares of company stock worth $23,825,554. 7.20% of the stock is owned by insiders.

NYSE SYK opened at $189.04 on Wednesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.02 and a quick ratio of 1.41. The company has a market cap of $72.17 billion, a P/E ratio of 25.86, a PEG ratio of 2.38 and a beta of 0.88. Stryker Co. has a 52 week low of $144.75 and a 52 week high of $199.85.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 29th. The medical technology company reported $2.18 EPS for the quarter, topping the consensus estimate of $2.15 by $0.03. The firm had revenue of $3.80 billion during the quarter, compared to analyst estimates of $3.73 billion. Stryker had a net margin of 26.12% and a return on equity of 27.60%. Research analysts forecast that Stryker Co. will post 8.13 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, March 28th. This represents a $2.08 annualized dividend and a dividend yield of 1.10%. Stryker’s dividend payout ratio (DPR) is presently 28.45%.

ILLEGAL ACTIVITY NOTICE: “Stryker Co. (SYK) Shares Sold by Edmp Inc.” was published by Modern Readers and is the sole property of of Modern Readers. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.modernreaders.com/news/2019/04/17/stryker-co-syk-shares-sold-by-edmp-inc.html.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: Buyback For Investors Defined

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.